Exp Clin Endocrinol Diabetes 2005; 113 - V2_22
DOI: 10.1055/s-2005-862806

Thyrotropin-receptor signalling in follicular carcinoma cells: Evidence for G13-dependent ERK1/2 stimulation via EGF-receptor transactivation

TRH Büch 1, D Hager 1, N Nowak 1, H Biebermann 2, A Grüters 2, H Barth 3, K Aktories 3, T Gudermann 1
  • 1Philipps-Universität Marburg, Fachbereich Medizin, Pharmakologie und Toxikologie, Marburg
  • 2Humboldt-Universität Berlin, Otto Heubner Centrum für Kinderheilkunde und Jugendmedizin, Pädiatrische Endokrinologie, Berlin
  • 3Albert-Ludwigs-Universität Freiburg, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Freiburg

Activation of the thyrotropin receptor (TSH-R) exhibits growth stimulatory as well as differentiating effects upon normal and neoplastic thyroid epithelium. The TSH-R recruits Gs, Gi/o, Gq/11, and G12/13 proteins and thus may instigate a plethora of signalling pathways. With respect to proliferative responses, involvement of ERK1/2 was tested in previous investigations, yet with somewhat incoherent results. In the present study, a human follicular thyroid carcinoma cell line (FTC-133) without functional TSH-R and FTC-133 cells stably expressing either wild-type (FTC-133wt) or mutated (FTC-133Y601H) TSH-R were investigated. In FTC-133Y601H-cells, Gq/11 coupling of TSH-R is selectively disrupted while other pathways, e.g. cAMP formation, are still functional. In FTC-133wt and FTC-133Y601H cells – but not in FTC-133 cells without TSH-R – stimulation with TSH activated ERK1/2. This was mediated by EGF receptor (EGF-R) transactivation since EGF-R inhibitor AG1478, anti-HB-EGF antibodies, and matrix metalloproteinase inhibitors blocked ERK1/2 activation. To further characterize the distinct G-protein-dependent pathway of ERK1/2 activation, inhibitors of phospholipase C and protein kinase C as well as the Ca2+-chelator BAPTA and pertussis toxin were tested. None of them inhibited ERK1/2 activation by TSH suggesting a Gq/11- and Gi/o-independent mechanism. In addition, inhibition of cAMP-dependent protein kinase did not abolish ERK1/2 activation and adenylyl cyclase stimulation by forskolin did not activate ERK1/2, thus indicating, that Gs was not involved either. However, dominant negative Gα13 mutants hampered ERK1/2 activation whereas dominant negative Gα12 mutants were ineffective. This could be substantiated using Gα12 and Gα13-specific siRNA whereas inhibitors of possible down-stream effectors, i.e. RhoA and Rho kinase, were without effect. These data demonstrate the first biological read-out for TSH-R mediated Gα13 activation and underline the non-redundancy of Gα12 and Gα13 dependent signalling.